Page last updated: 2024-08-26

bosentan anhydrous and bms 193884

bosentan anhydrous has been researched along with bms 193884 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barrish, JC; Bird, E; Chen, P; Chong, S; Gu, Z; Hermsmeier, M; Humphreys, WG; Koplowitz, B; Leith, L; Liu, EC; Marino, A; Mathur, A; Moreland, S; Morrison, RA; Murugesan, N; Spergel, S; Trippodo, N; Waldron, T; Webb, ML; Young, M; Zhang, R	1
Berens, KL; Blok, N; Bourgoyne, AR; Brock, TA; Bui, H; Decker, ER; Dixon, RA; Holland, GW; Knowles, V; Wang, J; Wu, C; You, TJ	1
Bolli, MH; Boss, C; Gatfield, J	1

Reviews

1 review(s) available for bosentan anhydrous and bms 193884

Article	Year
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective. Bioorganic & medicinal chemistry letters, 2016, 08-01, Volume: 26, Issue:15 Topics: Bosentan; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Humans; Molecular Structure; Pyrimidines; Receptors, Endothelin; Structure-Activity Relationship; Sulfonamides	2016

Trials

1 trial(s) available for bosentan anhydrous and bms 193884

Article	Year
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist. Journal of medicinal chemistry, 2004, Apr-08, Volume: 47, Issue:8 Topics: Administration, Oral; Animals; Antihypertensive Agents; Biological Availability; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin A Receptor Antagonists; Humans; Isoxazoles; Ligands; Male; Models, Molecular; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Structure-Activity Relationship; Sulfones	2004

Article

Year

Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.

Journal of medicinal chemistry, 2004, Apr-08, Volume: 47, Issue:8

Topics: Administration, Oral; Animals; Antihypertensive Agents; Biological Availability; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin A Receptor Antagonists; Humans; Isoxazoles; Ligands; Male; Models, Molecular; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Structure-Activity Relationship; Sulfones

2004

Other Studies

1 other study(ies) available for bosentan anhydrous and bms 193884

Article	Year
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective Journal of medicinal chemistry, 2003, Jan-02, Volume: 46, Issue:1 Topics: Administration, Oral; Animals; Blood Pressure; Caco-2 Cells; Carotid Arteries; CHO Cells; Cricetinae; Endothelin Receptor Antagonists; Humans; In Vitro Techniques; Isoxazoles; Macaca fascicularis; Male; Muscle Contraction; Oxazoles; Rabbits; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Structure-Activity Relationship; Sulfonamides	2003

Article

Year

Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective

Journal of medicinal chemistry, 2003, Jan-02, Volume: 46, Issue:1

Topics: Administration, Oral; Animals; Blood Pressure; Caco-2 Cells; Carotid Arteries; CHO Cells; Cricetinae; Endothelin Receptor Antagonists; Humans; In Vitro Techniques; Isoxazoles; Macaca fascicularis; Male; Muscle Contraction; Oxazoles; Rabbits; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Structure-Activity Relationship; Sulfonamides

2003